AHZANTIVE DIN 02562928
Health Canada record
| Active ingredient(s) | AFLIBERCEPT 2 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravitreal |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | S01LA05 AFLIBERCEPT |
| Original market date | |
| Current status date | 19-Nov-2025 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing AFLIBERCEPT
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02554178 | AFLIVU | APOTEX INC | Solution | AFLIBERCEPT 2 MG | Marketed |
| 02554194 | AFLIVU | APOTEX INC | Solution | AFLIBERCEPT 2 MG | Marketed |
| 02562529 | ENZEEVU | SANDOZ CANADA INCORPORATED | Solution | AFLIBERCEPT 2 MG | Approved |
| 02562510 | ENZEEVU | SANDOZ CANADA INCORPORATED | Solution | AFLIBERCEPT 2 MG | Marketed |
| 02563045 | EYDENZELT | CELLTRION INC. | Solution | AFLIBERCEPT 2 MG | Marketed |
| 02563037 | EYDENZELT | CELLTRION INC. | Solution | AFLIBERCEPT 2 MG | Marketed |
| 02415992 | EYLEA | BAYER INC | Solution | AFLIBERCEPT 2 MG | Marketed |
| 02505355 | EYLEA | BAYER INC | Solution | AFLIBERCEPT 2 MG | Marketed |
| 02554798 | EYLEA HD | BAYER INC | Solution | AFLIBERCEPT 8 MG | Marketed |
| 02545004 | EYLEA HD | BAYER INC | Solution | AFLIBERCEPT 8 MG | Marketed |
| 02561883 | OPUVIZ | SAMSUNG BIOEPIS CO., LTD | Solution | AFLIBERCEPT 2 MG | Approved |
| 02561891 | OPUVIZ | SAMSUNG BIOEPIS CO., LTD | Solution | AFLIBERCEPT 2 MG | Approved |
| 02550628 | PAVBLU | AMGEN CANADA INC | Solution | AFLIBERCEPT 2 MG | Approved |
| 02550636 | PAVBLU | AMGEN CANADA INC | Solution | AFLIBERCEPT 2 MG | Marketed |
| 02535858 | YESAFILI | BIOCON BIOLOGICS CANADA INC | Solution | AFLIBERCEPT 2 MG | Marketed |
| 02558238 | YESAFILI | BIOCON BIOLOGICS CANADA INC | Solution | AFLIBERCEPT 2 MG | Marketed |
| 02421089 | ZALTRAP | SANOFI-AVENTIS CANADA INC | Solution | AFLIBERCEPT 200 MG | Cancelled Post Market |
| 02421070 | ZALTRAP | SANOFI-AVENTIS CANADA INC | Solution | AFLIBERCEPT 100 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36404 | 2025-11-19 | New Drug Submission (NDS) |